Literature DB >> 8391336

Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study.

T Lehtinen1, J Lumio, J Dillner, M Hakama, P Knekt, M Lehtinen, L Teppo, P Leinikki.   

Abstract

We estimated Epstein-Barr virus (EBV) antibody-associated relative risks (RR) of malignant lymphoma/leukemia within a cohort of 39,000 healthy Finnish adults followed up for 12 years. Antibody analyses to EBV capsid antigen (VCA), early antigen (EA), and nuclear antigens (EBNA, EBNA1, and EBNA2) were based on concomitantly evaluated ELISA techniques. No increased risk was associated with mere EBV seropositivity. However, elevated EBV EA and EBNA antibody levels were associated with a statistically significant excess risk of malignant lymphoma/leukemia (RREA = 3.4, 95 percent confidence interval [CI] = 1.0-11.0; RREBNA = 4.5, CI = 1.2-16.9). These elevated antibody responses may be due either to destruction of neoplastic EBV positive B-cells and/or to activation of latent EBV infection early in the lymphomagenesis.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8391336     DOI： 10.1007/bf00051312

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN： 0957-5243            Impact factor:   2.506


  30 in total

1.  Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein.

Authors:  P M Vestlev; G Pallesen; K Sandvej; S J Hamilton-Dutoit; S M Bendtzen
Journal:  Int J Cancer       Date:  1992-02-20       Impact factor: 7.396

2.  Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis.

Authors:  K Falk; I Ernberg; R Sakthivel; J Davis; B Christensson; J Luka; M Okano; H L Grierson; G Klein; D T Purtilo
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

3.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

Review 5.  Epidemiology of Hodgkin's disease.

Authors:  S Grufferman; E Delzell
Journal:  Epidemiol Rev       Date:  1984       Impact factor: 6.222

6.  Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

Authors:  W Henle; G Henle; J Andersson; I Ernberg; G Klein; C A Horwitz; G Marklund; L Rymo; C Wellinder; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

7.  Herpes simplex virus type 2 infection and cervical cancer: a prospective study of 12 years of follow-up in Finland.

Authors:  M Lehtinen; M Hakama; R K Aaran; A Aromaa; P Knekt; P Leinikki; J Maatela; R Peto; L Teppo
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

8.  Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis.

Authors:  A Linde; B Kallin; J Dillner; J Andersson; L Jägdahl; A Lindvall; B Wahren
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

9.  Detection of distinct Epstein-Barr virus genotypes in NPC biopsies from southern Chinese and Caucasians.

Authors:  M L Lung; G C Chang
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

10.  Infectious mononucleosis and Hodgkin's disease.

Authors:  N Muñoz; R J Davidson; B Witthoff; J E Ericsson; G De-Thé
Journal:  Int J Cancer       Date:  1978-07-15       Impact factor: 7.396
View more
  15 in total

1.  A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Brenda M Birmann; Ellen T Chang; Donna Spiegelman; Jon C Aster; Shumin M Zhang; Francine Laden
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort.

Authors:  Anneclaire J De Roos; Otoniel Martínez-Maza; Keith R Jerome; Dana K Mirick; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Kerstin L Edlefsen; Andrea Z Lacroix
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-24       Impact factor: 4.254

3.  Cohorts and privacy.

Authors:  H B Newcombe
Journal:  Cancer Causes Control       Date:  1994-05       Impact factor: 2.506

4.  Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.

Authors:  Lynn I Levin; Ellen T Chang; Richard F Ambinder; Evelyne T Lennette; Mark V Rubertone; Risa B Mann; Michael Borowitz; Edward G Weir; Susan L Abbondanzo; Nancy E Mueller
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

5.  Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection.

Authors:  B Winkelspecht; F Grässer; H W Pees; N Mueller-Lantzsch
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group.

Authors:  P Parkkonen; H Hyöty; J Ilonen; H Reijonen; S Ylä-Herttuala; P Leinikki
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 7.  Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Authors:  Anna E Coghill; Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2014-08-28       Impact factor: 4.897

8.  Concentrations of organochlorines related to titers to Epstein-Barr virus early antigen IgG as risk factors for hairy cell leukemia.

Authors:  M Nordström; L Hardell; G Lindström; H Wingfors; K Hardell; A Linde
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

9.  Epstein-Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study.

Authors:  Y Kim; A Shin; J Gwack; K-P Ko; C-S Kim; S K Park; Y-C Hong; D Kang; K-Y Yoo
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

10.  Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures?

Authors:  Lennart Hardell; Mikael Eriksson
Journal:  Environ Health Perspect       Date:  2003-11       Impact factor: 9.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.